New Mycoplasma pneumoniae Study Findings Have Been Reported from Seoul National University (Changes in Pediatric Tetracycline Prescribing Patterns During the 2024 Mycoplasma pneumoniae Pneumonia Epidemic in the Republic of Korea): Gram-Negative Bacteria – Mycoplasma pneumoniae

2026 AUG 26 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Current study results on Gram-Negative Bacteria - Mycoplasma pneumoniae have been published. According to news reporting out of Seongnam, South Korea, by NewsRx editors, research stated, “Although macrolide-resistant Mycoplasma pneumoniae pneumonia prevalence exceeds 90% in the Republic of Korea, health insurance reimbursement policies historically restrict guideline-recommended tetracycline use in children aged <12 years. After a post-pandemic outbreak, reimbursement coverage was expanded in late 2023, and clinical guidelines were updated in early 2024 to permit tetracycline use in this age group.”

Our news journalists obtained a quote from the research from Seoul National University, “This study evaluated the impact of these policy changes on nationwide pediatric prescribing. Using national prescription and sentinel surveillance data (2015-2025), an interrupted time-series analysis assessed changes in tetracycline prescribing responsiveness to epidemic intensity, with the intervention point set to March 2024. Pediatric tetracycline prescribing remained low until 2023 but increased markedly in 2024, with annual standardized prescribing rates (units per 1000 population) rising from <0.01 to 0.22, 0.01 to 0.74 and 0.91 to 1.74 in the 0-4, 5-9 and 10-14 year age groups, respectively. Before the intervention, prescribing showed no significant association with epidemic activity in any age group; after the intervention, significant synchronization emerged in children aged <15 years (P < 0.001). Prescribing rates lagged the initial epidemic rise by approximately 2 months but declined in parallel as the outbreak resolved. After the 2024 policy changes, tetracycline prescriptions rose and fell in sync with Mycoplasma pneumoniae pneumonia epidemic activity.”

According to the news editors, the research concluded: “This rapid de-escalation argues against persistent prescription drift and suggests active clinical judgment rather than passive exploitation of newly available access.”

This research has been peer-reviewed.

For more information on this research see: Changes in Pediatric Tetracycline Prescribing Patterns During the 2024 Mycoplasma pneumoniae Pneumonia Epidemic in the Republic of Korea. Pediatric Infectious Disease Journal, 2026. Pediatric Infectious Disease Journal can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; Pediatric Infectious Disease Journal - http://journals.lww.com/pidj/pages/default.aspx)

Our news journalists report that additional information may be obtained by contacting Ye Kyung Kim, Dept. of Pediatrics, Bundang Hospital, Seoul National University, Seongnam, South Korea. Additional authors for this research include Seung Ha Song, Bin Ahn, Sujin Choi, Young Joo Sohn, Young June Choe and Youn Young Choi.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/inf.0000000000005356. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the Pediatric Infectious Disease Journal is: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)